About Dizal Pharma
Dizal Pharma is a company based in Pudong (China) founded in 2017. Dizal Pharma has raised $100 million across 1 funding round from investors including SANY Group, Lilly Asia Ventures and Trinity Innovation Fund. Dizal Pharma operates in a competitive market with competitors including AmerisourceBergen, Quanyuantang Pharmacy, Guiyang Xintian Pharmaceutical, Sinopharm Online and Jiuzhitang, among others.
- Headquarter Pudong, China
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$100 M (USD)
in 1 rounds
-
Latest Funding Round
$100 M (USD), Series A
Aug 20, 2020
-
Investors
SANY Group
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Dizal Pharma
Unlock access to complete
Funding Insights of Dizal Pharma
Dizal Pharma has successfully raised a total of $100M through 1 strategic funding round. The most recent funding activity was a Series A round of $100 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Dizal Pharma
Dizal Pharma has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include SANY Group, Lilly Asia Ventures and Trinity Innovation Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A venture capital firm focused on biotech innovation investments.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Manufacturer of construction & mining equipment, port, and oil drilling machinery
|
Locked | Locked | Locked |
Investor details for Dizal Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Dizal Pharma
Investment portfolio details for Dizal Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Dizal Pharma
Detailed financials for Dizal Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dizal Pharma Comparisons
Peer comparison for Dizal Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Dizal Pharma
Dizal Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AmerisourceBergen, Quanyuantang Pharmacy, Guiyang Xintian Pharmaceutical, Sinopharm Online and Jiuzhitang, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical distribution and supply chain services are provided globally.
|
|
| Locked | Locked | Locked |
Medical and pharmaceutical products are retailed offline and online.
|
|
| Locked | Locked | Locked |
Pharmaceutical company in China
|
|
| Locked | Locked | Locked |
Pharmaceutical products are sold via an e-commerce platform in China.
|
|
| Locked | Locked | Locked |
Distributor of pharmaceutical products
|
Detailed competitors of Dizal Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dizal Pharma
Complete news archive for Dizal Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dizal Pharma
Dizal Pharma was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Dizal Pharma is headquartered in Pudong, China. It is registered at Pudong, Shanghai, China.
Dizal Pharma is a funded company, having raised a total of $100M across 1 funding round to date.
Dizal Pharma was founded in 2017 and is headquartered in Pudong, China. Operations are centered in the biopharmaceutical sector, with emphasis on discovering and developing novel small-molecule drugs for oncology and other unmet medical needs. Clinical-stage assets are advanced through partnerships and internal RD efforts, targeting global markets while maintaining a base in Asia. Limited public details are available on specific services or revenue streams.
Dizal Pharma's top competitors include AmerisourceBergen, Guiyang Xintian Pharmaceutical and Quanyuantang Pharmacy.
Dizal Pharma has 4 investors. Key investors include SANY Group, Lilly Asia Ventures, Trinity Innovation Fund, and HongShan.